Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $3.43B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: PVH stock price vs RPRX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RPRX's multiple
Needs RPRX P/E.
Implied fair value · at PVH's multiple
Needs PVH P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PVH FY 2026 (ended Feb 1, 2026) · RPRX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 60% equity / 40% debt · EV / Revenue 0.56x · EV / EBITDA 10.03x
Capital structure 73% equity / 27% debt · EV / Revenue 14.10x · EV / EBITDA 31.91x
RPRX carries the larger enterprise value at $33.54B against $5.05B; PVH trades on the lower EV / Revenue multiple (0.56x vs 14.10x); PVH on the lower EV / EBITDA (10.03x vs 31.91x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PVH CORP. · implied price per share
Bear
$67.33
Base
$85.11
Bull
$108.27
Royalty Pharma plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.48x
0.96x
Net debt / EBITDA
Leverage against operating earnings
3.21x
8.29x
Cash and equivalents
Liquid reserves on the balance sheet
$701.50M
$618.70M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$2.32B
$9.33B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
